NCT04625985View on ClinicalTrials.gov

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

March 8, 2021

Study Completion Date

March 18, 2021

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

DRUG

Metformin Glycinate

Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment

DRUG

Placebo oral tablet

Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment

Trial Locations (1)

01120

The American British Cowdray Medical Center, I.A.P, Mexico City

All Listed Sponsors

lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY

NCT04625985 - Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. | Biotech Hunter | Biotech Hunter